Patient Preference With Visicol Tablet Preparation for Colonoscopy

This study has been completed.

First Received: April 24, 2006 Last Updated: December 17, 2007 History of Changes

Sponsors and Collaborators:	Mayo Clinic InKine Pharmaceutical
Information provided by:	Mayo Clinic
ClinicalTrials.gov Identifier:	NCT00318305

Purpose

The purpose of this study is to determine patient preference and acceptance of tablet sodium phosphate bowel preparation in patients who had polyethylene glycol (PEG) solution for their prior colonoscopy. This study will provide answers related to the patient preferences and their acceptance of this new method of bowel preparation.

Condition
Preparation for Colonoscopy

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	Patient Preference and Acceptance With Sodium Phosphate Tablet Preparation for Colonoscopy: A Prospective Study

Resource links provided by NLM:

MedlinePlus related topics: Colonoscopy

U.S. FDA Resources

Further study details as provided by Mayo Clinic:

Biospecimen Retention: None Retained

Biospecimen Description:

Enrollment:	53
Study Start Date:	March 2005
Study Completion Date:	April 2006

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Criteria

Inclusion Criteria:

Prior colonoscopy with PEG solution in the past one year
Must be able to swallow tablets

Exclusion Criteria:

Patients below 18 years and above 100 years.
Congestive heart failure
Chronic renal failure
Pre-existing electrolyte disorder
Pre-existing mega-colon or a motility disorder.
Patients with pre-existing seizure disorder.
Patients scheduled for colonoscopy after 1:00 p.m. will be excluded from the study.
Pregnant or lactating women

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00318305

Locations

United States, Arizona
Mayo Clinic
Scottsdale, Arizona, United States, 85259

Sponsors and Collaborators

Mayo Clinic

InKine Pharmaceutical

Investigators

Principal Investigator:

Suryakanth R. Gurudu, M.D.

Mayo Clinic

More Information

No publications provided

Responsible Party:	Mayo Clinic ( Suryakanth Gurudu, MD )
Study ID Numbers:	392-05
Study First Received:	April 24, 2006
Last Updated:	December 17, 2007
ClinicalTrials.gov Identifier:	NCT00318305 History of Changes
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Sodium phosphate

ClinicalTrials.gov processed this record on August 30, 2009